Onivyde, also known as irinotecan liposome, is an injectable chemotherapy drug used to treat pancreatic cancer [1]. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [2].
How is Onivyde administered?
Onivyde is administered intravenously, meaning it is given through an IV infusion [1]. The dosage and frequency of administration depend on the specific treatment regimen and the patient's medical condition [3].
What types of pancreatic cancer does Onivyde treat?
Onivyde is indicated for the treatment of pancreatic adenocarcinoma in patients who have been previously treated with gemcitabine-based chemotherapy [2]. It is typically used in combination with other chemotherapy drugs, such as fluorouracil and leucovorin [4].
How does Onivyde work?
Onivyde works by delivering irinotecan in a liposomal capsule, which is designed to release the active drug over time [5]. Irinotecan inhibits topoisomerase I, an enzyme essential for DNA replication and repair. By inhibiting this enzyme, irinotecan causes DNA damage and leads to the death of cancer cells [2][6].
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis (mouth sores) [1][7]. More serious side effects can occur, such as severe diarrhea, neutropenia (low white blood cell count), and febrile neutropenia [2].
What is the patent status for Onivyde?
Information regarding specific patents and their expiration dates for Onivyde can be found on DrugPatentWatch.com [8]. Patent expiry dates are crucial for determining when generic or biosimilar versions of a drug may become available [9].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [1].